<DOC>
	<DOCNO>NCT00775437</DOCNO>
	<brief_summary>The main objective study evaluate safety adalimumab patient 2 &lt; 4 year age ≥ 4 year age weigh &lt; 15 kg , moderately severely active polyarticular juvenile idiopathic arthritis ( JIA ) polyarticular course JIA .</brief_summary>
	<brief_title>Active Juvenile Idiopathic Arthritis ( JIA ) Compassionate Use</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . A parent guardian voluntarily sign date informed consent form , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) , nature study explain subject 's parent legal guardian opportunity ask question . The informed consent must sign studyspecific procedure perform medication discontinue purpose study . The parent must also willing comply requirement study protocol . 2 . Subject disease diagnosis moderately severely active polyarticular polyarticular course juvenile idiopathic arthritis ( JIA ; define arthritis affect &gt; = 5 joint time treatment initiation ) . This correspond International League Associations Rheumatology category polyarticular rheumatoid factor positive ( RF+ ) , polyarticular Rheumatoid factor negative ( RF ) disease , extend oligoarthritis disease . 3 . Subject must age 2 &lt; 4 year old moderately severely active polyarticular JIA polyarticular course JIA age 4 great weigh &lt; 15 kg moderately severely active polyarticular JIA polyarticular course JIA , per International League Associations Rheumatology ( ILAR ) criterion . 4 . Subject judge generally good health determine Investigator base upon result medical history , laboratory profile , physical examination perform Screening confirm Baseline . This include , limited , normal cardiopulmonary normal neurological exam result . 5 . Parent legal guardian must able willing administer subcutaneous ( SC ) injection qualify person available administer SC injection . 6 . Parent legal guardian must willing actively supervise storage administration study drug ensure time dose accurately record subject 's diary . 7 . Subject must negative purified protein derivative ( PPD ) test ( equivalent ) Screening . If subject positive ( great equal 5mm induration ) PPD test result , chest xray ( posterioranterior [ PA ] lateral view ) must perform . If subject positive test ( equivalent ) , past ulcerative reaction PPD placement , and/or chest x ray consistent tuberculosis [ TB ] exposure , subject may enrol study . 8 . For subject European Union [ EU ] , subject must previously fail , insufficient response , intolerant least one DiseaseModifying Anti Rheumatic Drug ( DMARD ) . 1 . Subject prior exposure Tysabri® ( natalizumab ) Raptiva® ( efalizumab ) biologic therapy , Orencia® ( abatacept ) , Kineret® ( anakinra ) , Actemra® ( tocilizumab ) , Rituxan® ( rituximab ) . Any previous use antitumor necrosis factor [ TNF ] agent , include Enbrel® ( etanercept ) , Remicade® ( infliximab ) , Cimzia® ( certolizumab pegol ) , Simponi® ( golimumab ) , adalimumab also prohibit . 2 . Infection ( ) require treatment intravenous ( IV ) antiinfectives within 30 day prior Baseline Visit oral antiinfectives within 14 day prior Baseline Visit . 3 . Subject undergone joint surgery within precede two month Screening Visit ( joint assess within study ) . 4 . Subject previous diagnosis condition could cause arthritis polyarticular JIA . 5 . Subject history allergic reaction significant sensitivity constituent study drug , adalimumab . 6 . Subject treated investigational drug chemical biologic nature within minimum 30 day 5 half life ( whichever longer ) drug prior Baseline visit . Should biologics become approved , would continue exclude . 7 . Subject poorly control medical condition , uncontrolled diabetes , unstable heart disease , recent cerebrovascular accident , seizure disorder , condition , opinion Investigator , would put subject risk participation study . 8 . Subject history clinically significant hematologic ( e.g. , severe anemia , leukopenia , thrombocytopenia , clot disorder ) , renal , liver disease ( e.g. , fibrosis , cirrhosis , hepatitis ) , active gastroenteric ulcer . 9 . Subject consider Investigator , reason , unsuitable candidate study . 10 . Subject evidence active TB infection . 11 . Subject history moderate severe congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) , recent cerebrovascular accident thrombotic event condition , opinion investigator , would put subject risk participation protocol . 12 . Evidence dysplasia history malignancy ( include lymphoma leukemia ) . 13 . History demyelinate disease ( include myelitis ) neurologic symptom suggestive central nervous system [ CNS ] demyelinate disease . 14 . History invasive fungal infection ( e.g. , listeriosis , histoplasmosis ) , active viral disorder , human immunodeficiency virus ( HIV ) infection . 15 . Positive Hepatitis B test result . 16 . Chronic recur infection active TB . 17 . Screening laboratory analysis show follow abnormal result : electrocardiogram [ ECG ] clinically significant abnormality ; Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 1.75 upper limit reference range ; Total bilirubin &gt; =3 mg/dL ; Serum creatinine &gt; 1.6 mg/dL ( convert mmol/L ) . 18 . Evidence dysplasia history malignancy ( include lymphoma leukemia ) successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>juvenile idiopathic arthritis</keyword>
	<keyword>compassionate use</keyword>
	<keyword>open label</keyword>
</DOC>